Gemcitabine for Pancreatic Cancer
This trial will study the effects of adding L-glutamine to standard chemo for advanced pancreatic cancer. 16 patients will be enrolled at Cedars-Sinai.
- Pancreatic Cancer
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
How many participants are benefiting from this clinical experiment?
"Affirmative. Details on clinicaltrials.gov reveal that this medical trial is presently enrolling patients; it was initially published on May 13th 2021 and has since been updated in August of 2022. This investigation requires 16 volunteers at two distinct centres."
Could you walk me through the existing research regarding L-glutamine?
"Currently, 1118 studies are underway exploring the efficacy of L-glutamine. Out of those trials, 322 have reached Phase 3 testing. The vast majority of these clinical operations are based in Shanghai; however there is a total 59459 sites running tests with this medication globally."
What medical conditions can be aided by the use of L-glutamine?
"L-glutamine is regularly prescribed to patients undergoing post-anthracycline adjuvant treatments. Moreover, this medication can be beneficial for treating metastatic bladder cancer, neoplasm metastasis and locally advanced non-small cell lung cancer."
Is there still an opportunity to partake in this experiment?
"Affirmative; according to data on clinicaltrials.gov, the trial is seeking participants at this time. Commencing initially on May 13th 2021, it was most recently modified on August 31st 2022 and seeks 16 patients from two distinct sites."
What potential risks remain associated with the ingestion of L-glutamine?
"As L-Glutamine is currently in its first phase of clinical trials, the safety score determined by Power was 1 due to a lack of evidence regarding efficacy and protection."